DAR File No.: 41811
Filed: 06/14/2017 09:36:39 AMNOTICE OF REVIEW AND STATEMENT OF CONTINUATION
Concise explanation of the particular statutory provisions under which the rule is enacted and how these provisions authorize or require the rule:
This rule is authorized by Section 26-18-2.4 which allows the Department of Health to reimburse for certain classes of drugs on the Preferred Drug List (PDL), spells out prior authorization requirements, and sets forth prescription override exceptions. In addition, Section 26-18-3 requires the Department to implement the Medicaid drug program through administrative rules, and Section 26-1-5 grants the Department the authority to adopt these rules for implementation.
Summary of written comments received during and since the last five-year review of the rule from interested persons supporting or opposing the rule:
The Department did not receive any written or oral comments regarding this rule.
Reasoned justification for continuation of the rule, including reasons why the agency disagrees with comments in opposition to the rule, if any:
The Department will continue this rule because it implements PDL eligibility, specifies the purpose of the PDL in relation to certain classes of drugs, clarifies that coverage is based on clinical and cost effectiveness, spells out prior authorization requirements, implements Pharmacy and Therapeutics (P&T) Committee composition and membership, implements P&T Committee responsibilities and functions, and sets forth provisions for the P&T Committee to make determinations based on clinical and cost-related factors.
The full text of this rule may be inspected, during regular business hours, at the Office of Administrative Rules, or at:
Health
Health Care Financing, Coverage and Reimbursement Policy
CANNON HEALTH BLDG
288 N 1460 W
SALT LAKE CITY, UT 84116-3231Direct questions regarding this rule to:
- Craig Devashrayee at the above address, by phone at 801-538-6641, by FAX at 801-538-6099, or by Internet E-mail at cdevashrayee@utah.gov
Effective:
06/14/2017
Authorized by:
Joseph Miner, Executive Director
Document Information
- Effective Date:
- 6/14/2017
- Publication Date:
- 07/01/2017
- Type:
- Five-Year Notices of Review and Statements of Continuation
- Filed Date:
- 06/14/2017
- Agencies:
- Health, Health Care Financing, Coverage and Reimbursement Policy
- Authorized By:
- Joseph Miner, Executive Director
- DAR File No.:
- 41811
- Summary:
The Department did not receive any written or oral comments regarding this rule.
- CodeNo:
- R414-60B
- CodeName:
- {47225|R414-60B|R414-60B. Preferred Drug List}
- Link Address:
- HealthHealth Care Financing, Coverage and Reimbursement PolicyCANNON HEALTH BLDG288 N 1460 WSALT LAKE CITY, UT 84116-3231
- Link Way:
Craig Devashrayee, by phone at 801-538-6641, by FAX at 801-538-6099, or by Internet E-mail at cdevashrayee@utah.gov
- AdditionalInfo:
- More information about a Five-Year Notice of Review and Statement of Continuation is available online. The Portable Document Format (PDF) version of the Bulletin is the official version. The PDF version of this issue is available at https://rules.utah.gov/publicat/bull_pdf/2017/b20170701.pdf. The HTML edition of the Bulletin is a convenience copy. Any discrepancy between the PDF version and HTML version is resolved in favor of the PDF version. For questions regarding the content or ...
- Related Chapter/Rule NO.: (1)
- R414-60B. Preferred Drug List.